Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Cairn Homes profits grow in favourable market conditions

(Sharecast News) - Ireland-based housebuilder Cairn Homes posted a rise in full-year profit and revenue on Thursday "amid continuing favourable market conditions". In results for the year to the end of December 2024, the housebuilder said operating profit jumped 32% to €150m, with revenue up 29% at €859.9m from 2,241 units, versus 1,741 units a year earlier.

Basic earnings per share ticked up 41% to 17.9 cents.

Cairn said market conditions remain "very attractive", with "strong demand" for its energy-efficient new homes across all buyer profiles.

It added that state supports for its customers, a favourable mortgage market and the limited supply of competitively-priced and well-located new starter homes was continuing to drive positive momentum, with the enquiry lists across all of its active selling sites remaining at historic highs.

Cairn said it expects 2025 to be another strong year, with revenue growth "in excess of" 10% for the full year, operating profit of around €160m and return on equity of around 15.5%.

Chief executive Michael Stanley said: "We took a material step, right across our business, in operational performance and volume delivery in 2024. We also made significant progress in our financial performance based on a foundation of continuous and substantial investment in the delivery of new homes for private buyers and for the state.

"We will continue to be relentless in driving efficiencies through scale, innovation, digital and sustainable construction to deliver new homes at pace, scale and value for money. We look forward to another strong year of growth in housing output."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.